See this article Model-based decision rules reduce the risk of molecular relapse after cessation of TKI therapy in CML
See also The French trial called STIM (Stop Imatinib)
Model-based decision rules reduce the risk of molecular relapse after cessation of TKI therapy in CML
Started by
cousineg
, Nov 26 2012 02:18 PM
1 reply to this topic
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
